<DOC>
	<DOCNO>NCT02091414</DOCNO>
	<brief_summary>This study investigate efficacy safety CellCept ( 1.5-2g/day po ) , combination standard care regimen cyclosporine A ( trough level 150-200ng/mL ) steroid , patient receive heart transplant . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study CellCept ( Mycophenolate Mofetil ) Combination Therapy Heart Transplant Patients .</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; patient receive first heart transplant ( single organ transplant ) . patient positive donorspecific crossmatch time transplantation ; patient antibodytreated acute rejection ; know contraindication treatment sirolimus ; history malignancy , excise nonmelanoma skin cancer recur 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>